Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268214 · ClinicalTrials.gov registry record · Phase 3
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 833
- Enrollment target
NCT02268214: Completed Phase 3 study, sponsored by AstraZeneca.
NCT02268214 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 833 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02268214, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 833 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
Primary Outcome
Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model\[RMM\]).
Interventions
- DRUG Dapagliflozin
- DRUG Placebo for dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 833 participants |
| Start Date | 2014-11-11 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 3 |
What the finished NCT02268214 record still lists
NCT02268214 is an interventional study that assigns participants to a tested intervention. The registered 833 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT02268214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02268214 about?
NCT02268214 is a clinical study titled "Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes". The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
What is the current status of trial NCT02268214?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 833 participants. The study started on 2014-11-11. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT02268214?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo for dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02268214?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02268214's enrollment target sits among peer trials
833 397th of 2000 higher than 1,604 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
- NCT03670524 · 835 participants · NA
Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project
- NCT02118467 · 836 participants · Phase 4
Vasoactive Drugs in Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI